Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: We reviewed clinical trials on active and passive anti-β-amyloid (Aβ) immunotherapy for the treatment of Alzheimer's disease with a particular focus on monoclonal antibodies against Aβ. RECENT FINDINGS: Studies on anti-Alzheimer's disease immunotherapy published in the period from January 2012 to October 2013 were reviewed. SUMMARY: Both active and passive anti-Aβ immunotherapies were shown to clear brain Aβ deposits. However, an active anti-Aβ vaccine (AN1792) has been discontinued because it caused meningoencephalitis in 6% of Alzheimer's disease patients treated. Among passive immunotherapeutics, two Phase III clinical trials in mild-to-moderate Alzheimer's disease patients with bapineuzumab, a humanized monoclonal antibody directed at the N-terminal sequence of Aβ, were disappointing. Another antibody, solanezumab, directed at the mid-region of Aβ, failed in two Phase III clinical trials in mild-to-moderate Alzheimer's disease patients. A third Phase III study with solanezumab is ongoing in mildly affected Alzheimer's disease patients based on encouraging results in this subgroup of patients. Second-generation active Aβ vaccines (ACC-001, CAD106, and Affitope AD02) and new passive anti-Aβ immunotherapies (gantenerumab and crenezumab) are being tested in prodromal Alzheimer's disease patients, in presymptomatic individuals with Alzheimer's disease-related mutations, or in asymptomatic individuals at risk of developing Alzheimer's disease to definitely test the Aβ cascade hypothesis of Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“Several different Ab species with overlapping size and morphology have been described [Ab-dimers, low-molecular weight oligomers, globulomers, Ab-derived diffusible ligands (ADDLs), protofibrils, and amylospheroids] [16], and recent evidence has implicated oligomeric Ab and ADDLs in cognitive decline [17,18].”
BackgroundRetractedClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 5×
“Unautho clusters (NFTs) composed of paired helical filaments of hyperphosphorylated tau protein, a microtubuleassociated protein, and extracellular protein aggregates (senile plaques).”
BackgroundInfluentialBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 1×
“showed a significant decrease in brain Ab levels, reduced brain senile plaque pathology, and improved cognition, beneficial effects observed using a variety of antibodies that differed in Abbinding properties [59,60].”
BackgroundRevising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 1×
“Furthermore, the recent introduction of new diagnostic criteria for Alzheimer’s disease based on specific cognitive patterns and reliable biomarkers [72] may open a new paradigm of therapeutic intervention, based on the distinction of preclinical states of Alzheimer’s disease in which individuals are free of cognitive…”
BackgroundIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731 · cited 5×
“The humanized IgG2 monoclonal antibody ponezumab (PF-04360365, Pfizer, Cambridge, UK), targeting the free C-terminus of Ab1–40, specifically Ab33–40 [78], after two successful Phase I trials [79,80], given the negative results with respect to clinical efficacy of two Phase II studies (ClinicalTrials.gov Identifiers: N…”
BackgroundInfluentialFormation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 1×
“Therefore, if immunization begins at earlier stages of the disease, the Ab-lowering effects could have increased cognitive benefits [34,35].”
Background
Cited by
Therapeutic strategies for Alzheimer's disease in clinical trials
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 452
Neuroinflammation in Alzheimer’s disease
Zhang, F., & Jiang, L. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75546 · Cited by 276
Age-related hearing impairment—a risk factor and frailty marker for dementia and AD
Panza, F., Solfrizzi, V., & Logroscino, G. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.12 · Cited by 257
Self-citationWalker, D. G., Whetzel, A. M., Serrano, G., Sue, L. I., Beach, T. G., & Lue, L.-F. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.023 · Cited by 93
“Prevention of amyloid buildup and promotion of its removal using various strategies have been tested in a range of clinical trials, but they have generally not shown significant effects (Golde, 2014; Li et al., 2013; O’Banion, 2013; Panza et al., 2014; Winblad et al., 2014).”
BackgroundBurns, T. C., Li, M. D., Mehta, S., Awad, A. J., & Morgan, A. A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.021 · Cited by 79
Metadata
- Authors
- Panza, F., Logroscino, G., Imbimbo, B. P., & Solfrizzi, V.
- Venue
- Current Opinion in Psychiatry
- Published
- 2014-03
- Volume
- 27
- Issue
- 2
- Pages
- 128-137
- ISSN
- 0951-7367 (ISSN-L)
- OpenAlex
- W2037902576
- Cited by
- 98
- References
- 35
- FWCI
- 12.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? https://app.cochat.ai/papers/10.1097/yco.0000000000000041
- The paper
- Panza, F., Logroscino, G., Imbimbo, B. P., & Solfrizzi, V. (2014). Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0000000000000041
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.